Females have a higher odds of chronic rhinosinusitis (CRS) without nasal polyps than men, according to a study published ...
The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...
Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps. Dupixent ...
“The lining of our nose is complex, and the increased blood flow that goes through the lining of the nose can lead to ...
AstraZeneca and Amgen have received U.S. Food and Drug Administration (FDA) approval for TEZSPIRE® (tezepelumab-ekko) as an ...